α受体阻滞剂联合手术治疗前列腺增生继发间质性膀胱炎的疗效分析

Efficacy analysis of α-receptor blocker and surgical treatment for benign prostatic hyperplasia combined with interstitial cystitis

目的探讨α受体阻滞剂联合手术治疗前列腺增生继发间质性膀胱炎的疗效。方法根据随机抽签的原则将前列腺增生继发间质性膀胱炎患者120例分为治疗组与对照组各60例,所有患者都给予经尿道双极等离子前列腺电切术,治疗组同时在术后每天口服盐酸坦洛新缓释胶囊18 d。结果治疗后治疗组与对照组的有效率分别为96.7%与80.0%,2组对比,差异有统计学意义(P<0.01)。2组治疗前的国际前列腺症状评分(IPSS)与生活质量评分(QOL)评分对比,差异无统计学意义,治疗后两组的上述评分明显降低(P<0.05),同时治疗后治疗组的IPSS与QOL评分明显低于对照组(P<0.05)。两组治疗后的最大尿流率明显高于治疗前,而残余尿量明显低于治疗前,对比差异明显(P<0.05)。结论α受体阻滞剂联合手术治疗前列腺增生继发间质性膀胱炎能提高疗效,改善症状与尿动力学状况,从而提高预后生活质量。

[Objective]To investigate the efficacy of α-receptor blocker and surgical treatment for benign prostatic hyperplasia combined with interstitial cystitis.[nethods]120 patients with benign prostatic hyperplasia combined with interstitial cystitis were randomly divided into the treatment group and the control group, 60 cases in each group. All patients were given the transurethral bipolaiplasmakinetic resection of prostate, and the treatment group was treated with Tamsulosin Hydrochloride Sustained-release Capsules by oral administration for 18 days. [Results]After treatment, the response rate of the treatment group and the control group was 96.7% and 80.0% respectively, and difference was statistically significant （P〈0.01）. Before treatment, there were no statistically significant differences in international prostate symptom scores （IPSS） and quality of life （QOL） scores between two groups. The scores of IPSS and QOL after treatment decreased significantly in two group （P〈0.05）, and the scores of IPSS and QOL in the treatment group were significantly lower than those in the control group （P〈0.05）. In both two groups, the maximal urinary flow rates after treat were higher than those before treatment, while the residual urine volume after treat were significantly lower than those before treatment, and the differences were statistically significant （P〈0.05）.[Conclusion]The α-receptor blocker and surgical treatment can enhance efficacy of benign prostatic hyperplasia combined with interstitial cystitis, and improve symptoms and urodynamic status, so as to improve the quality of life and outcomes.